Objective: Although subtraction ictal SPECT coregistered to MRI (SISCOM) is clinically useful in epilepsy surgery evaluation, it does not determine whether the ictal-interictal subtraction difference is statistically different from the expected random variation between 2 SPECT studies. We developed a statistical parametric mapping and MRI voxel-based method of analyzing ictalinterictal SPECT difference data (statistical ictal SPECT coregistered to MRI [STATISCOM]) and compared it with SISCOM.
parametric mapping (SPM) analysis to compare a patient's ictal-interictal subtraction difference data with that of 2 nonictal SPECT studies from each of 26 control subjects. 9 A similar approach subsequently was developed and evaluated by others using control data from pairs of SPECT scans of each of 7 nonneurologic patients, but their method was not compared with other more established methods such as SISCOM. 10 The aim of this study was to objectively compare our new method of SPM analysis of ictal-interictal difference data (statistical ictal SPECT coregistered to MRI [STATISCOM]) with SISCOM by using the same raw SPECT data from each patient.
METHODS Standard protocol approval, registration, and patient consent. The study was approved by the Mayo Clinic Institutional Review Board. Written consent was obtained from the 11 control subjects. Otherwise, patient consent was not required in this retrospective clinical study.
Study subjects. Study patients were identified by medical record review. All subjects met the following eligibility criteria: 1) age 13 years and older; 2) no prior epilepsy surgery; 3) ictal and interictal SPECT studies performed from January 1, 1997, through December 1, 2005; 4) SPECT radioligand injected during the seizure (and before secondary generalization, if it occurred); 5) SPECT data sufficient for SISCOM and STATISCOM analysis; and 6) subsequent anterior temporal lobectomy with amygdalohippocampectomy. 11 Control subjects were 11 healthy volunteers (6 women) without a history of epilepsy, and each underwent 2 serial SPECT studies.
Classification of temporal lobe epilepsy subtypes. We categorized patients into 3 subtypes of temporal lobe epilepsy (TLE). First, patients with mesial TLE subtype had MRI evidence of hippocampal atrophy or other mesial temporal lesions. If patients were without lesions on MRI, intracranial EEG showed mesial temporal seizure onset. All patients with mesial TLE subtype did not have epileptogenic lesions elsewhere or conflicting neurophysiologic data. Second, patients with lateral neocortical TLE subtype had MRI evidence of epileptogenic lesions in the lateral temporal neocortex, without epileptogenic lesions elsewhere or conflicting neurophysiologic data. If patients were without lesions on MRI, intracranial EEG showed lateral temporal neocortical seizure onset. Third, patients with indeterminate seizure subtype had no lesions on MRI, and intracranial EEG was not performed; therefore, the TLE subtype could not be ascertained.
Control data. For the control subjects, SPECT difference data
were calculated by subtracting one study from the other (both studies were conducted in each volunteer). The difference data from the 11 volunteers served as the control against which each patient's ictal-interictal difference data were compared.
SPECT and SISCOM study procedure. 99m Tc-labeled ethyl cysteinate dimer (ECD) was injected IV as soon as seizure onset was noted during a prolonged video-EEG monitoring ses-sion. SPECT imaging was performed within 1 to 3 hours after the injection. Interictal SPECT imaging was performed when the patient had been seizure-free for at least 24 hours after the ictal SPECT imaging, as confirmed by continuous video-EEG monitoring.
Our method of SPECT image acquisition and reconstruction has been published previously. 2 The SISCOM method used 2 reconstructed and processed SPECT images from each individual. Images were coregistered to each other, one image was subtracted from the other to produce a difference SPECT image, and the difference image was coregistered to MRI. This process was performed with commercial image analysis software (ANALYZE 8.0, Biomedical Imaging Resource, Mayo Foundation, Rochester, MN), 2 except for the SPECTto-SPECT coregistration, which was performed using the automated image registration algorithm. 12 SPECT signals that were at least 2 standard deviations from the median value in the subtraction SPECT were used to detect hyperperfusion and hypoperfusion foci. STATISCOM procedure. Voxel-based analysis was performed using SPM2 software. 13 SPM analysis was performed using MATLAB (version 7.1; The Mathworks, Natick, MA). The difference SPECT image (derived as described above) and a mean, normalized SPECT image from each SPECT pair were imported into SPM2. Spatial normalization was achieved by warping the difference SPECT image into the standardized brain SPECT template provided by SPM2, using the mean, normalized image as the source image. Warping was achieved with a 12-parameter affine transform, using the General Linear Model and the Random Effects Model. The warp modified the difference image into the standard SPECT brain space; each voxel in the brain space was 2 ϫ 2 ϫ 2 mm. The brain mask provided by SPM2 was applied to the warped image to remove extracerebral pixels. The masked, spatially normalized images were smoothed by convolution with an isotropic Gaussian kernel of 16 mm.
Each subject's processed difference image was compared with that of the 11 controls. Statistical analysis was performed using a group comparison through an unpaired, 2-sample t test with the SPM contrast set to "1 Ϫ1" to identify ictal hyperperfusion and "Ϫ1 1" to identify ictal hypoperfusion with respect to the control group. No standardization to mean global uptake was necessary because normalization to a mean cerebral pixel intensity of 100 was already performed on all SPECT images during processing of SISCOM images (with ANALYZE software). The threshold for significance was set to p Ͻ 0.001 (uncorrected) for individual voxels. At the cluster level, only voxels with a threshold level of p Ͻ 0.05 (corrected) were deemed significant. The cluster extent threshold was set to 125, which was equivalent to the spatial resolution of SPECT in tissue. 14 The resultant t statistics data were transformed to normally distributed Z scores in the form of 3-dimensional SPM images and displayed on a standard Montreal Neurological Institute MRI template provided by SPM2.
The STATISCOM technique was not developed in a commercial format. The analysis techniques are in the public domain. Image reviews. SISCOM and STATISCOM images were assessed by two primary reviewers (E.L.S. and G.A.W.) who were blinded to all clinical, EEG, and brain MRI information. They identified up to 3 regions of hyperperfusion or hypoperfusion (in order of magnitude) in each SISCOM and STATISCOM study. SISCOM and STATISCOM images of each patient were not presented together, so the review of one study would not be influenced by the other study. If the primary reviewers disagreed, a third reviewer (B.P.M.), also blinded to all findings, assessed the images. Agreement of the third reviewer with one of the primary reviewers was considered the final localization of hyperperfusion or hypoperfusion changes. If the third reviewer failed to agree with either primary reviewer, the study was considered nonlocalizing. After all studies were reviewed, we compared STATISCOM and SISCOM with the following variables: 1) interobserver agreement rate between the 2 primary reviewers; 2) rate of localization of perfusion change; 3) rate of correct localization to TLE subtype; 4) concordance rate between regions of localized perfusion change; and 5) epilepsy surgery outcome.
RESULTS Patient population and SPECT injection
timing. A total of 453 consecutive patients underwent resective epilepsy surgery during the study period. Ictal and interictal SPECT studies were conducted in 106 temporal lobectomy patients who were 13 years or older and had no history of epilepsy surgery. SPECT data were incomplete or unavailable for analysis in 19 patients. Eighty-seven remaining patients (39 female [45%]) met all eligibility criteria for study inclusion. Median age at the time of the SPECT study was 34 years (range, 13-62 years). Median duration of the seizure in which 99m Tc-ECD was injected was 77 seconds (range, 13-529 seconds). Median time from seizure onset to injection was 25 seconds (range, 7-166 seconds), and median time from injection to end of seizure was 49 seconds (range, 0 -501 seconds). The seizure types occurring during ECD injection were complex partial seizures without secondary generalization (n ϭ 64 [74%]), complex partial seizures with secondary, generalized tonic-clonic seizures (n ϭ 20 [23%]), and simple partial seizures (n ϭ 3 [3%]). Only 52 patients (60%) had a localizing MRI abnormality (i.e., 40 patients with mesial temporal sclerosis, 3 with dysembryonic neuroepithelioma, 2 with traumatic encephalomalacia, 2 with gangliocytoma, 1 each with ganglioglioma, oligodendroglioma, tuberous sclerosis, cavernous hemangioma, and gliosis with corpora amylacea). Ictal scalp EEG showed localization to the frontotemporal region for 70 patients (80%).
Interobserver agreement rates. Interobserver agreement ( statistic) between the 2 primary blinded reviewers was considerably higher for STATISCOM images (87%; ϭ 0.81; 95% confidence interval [CI], 0.70 -0.92) than it was for SISCOM images (60%; ϭ 0.36; 95% CI, 0.20 -0.54). The interobserver agreement for STATISCOM was 45% higher than that for SISCOM (95% CI, 25%-65%). Seventy-two patients (83%) had at least 12 months of follow-up; of these, 53 (74%) had a seizure-free outcome (Engel Class I), 9 (13%) had a favorable outcome (Engel Class II), and 10 (14%) had a nonfavorable outcome (Engel Class III or IV).
The probability of a seizure-free outcome was higher when STATISCOM correctly localized the TLE subtype compared with when it was incorrect or had an indeterminate result. Of the 53 patients with correctly localizing STATISCOM, 43 (81%) had a seizure-free outcome, whereas 10 of the 19 patients (53%) with incorrect or indeterminate STATISCOM were seizure-free ( p ϭ 0.03; 95% CI, 5.4%-51.6%).
DISCUSSION
In the current study, we were able to show the superiority of STATISCOM, an SPMbased method of SPECT analysis, over SISCOM.
We developed STATISCOM to specifically address certain limitations of the SISCOM technique. We theorized that multiple foci of perfusion changes in an indeterminate SISCOM study may partly be due to random differences in SPECT images that are expected to occur between 2 serial SPECT studies. We addressed this limitation of SISCOM in a previous study using SPM to statistically compare the patient's ictal-interictal difference data against the difference data derived from pairs of nonictal SPECT studies from 26 control subjects. 9 The 26 pairs of SPECT studies consisted of 16 pairs of interictal studies from patients with epilepsy and 10 pairs from healthy volunteers. In contrast, the control data of our current study were derived only from healthy volunteers because a previous report showed that such data would improve the sensitivity of SPM SPECT analysis. 15 A previous study compared SPM SPECT analysis with subtraction SPECT analysis in 21 patients, but the authors reported that SPM SPECT analysis was not superior. 15 However, that study performed SPM analysis on ictal data only. In contrast, our method of STATISCOM used SPM to compare the difference data from a patient's ictal and interictal SPECT studies with that of 2 serial SPECT studies performed in healthy volunteers. The SPM analysis in the previous study 15 may have been confounded by the phenomenon of "pseudonormalization," which is defined as clinically significant ictal hyperperfusion at a seizure focus that has the appearance of normal perfusion. In these cases, the seizure focus is often hypoperfused relative to other brain regions during the interictal (baseline) state. 16 When a focal seizure occurs, the perfusion may be increased compared with baseline, but the increment may only approach or barely exceed a global threshold value for hyperperfusion. Pseudonormalization reduces the sensitivity with which an imaging study can detect the focus of hyperperfusion that corresponds to focal seizure activity.
The concept of SPM analysis of ictal-interictal SPECT difference data was also investigated previously by others 14 ; they reported no correlation with surgical outcome. Our different study outcome may be due to several reasons. Their method of ictalinterictal SPECT analysis by SPM spatially normalized (i.e., warped) the ictal and interictal images to the SPM SPECT template before subtracting to ob- tain difference images. In contrast, interictal SPECT in our STATISCOM method undergoes rigid transformation only to the ictal image before subtraction. We avoided warping SPECT data to the SPM SPECT template before subtraction to reduce image blurring and to avoid compounding effects of 2 registration errors. Ictal SPECT studies have better localization value than postictal SPECT studies, but most patients in the other study 14 had postictal SPECT injection; in contrast, all patients in our study had ictal SPECT injection. The SPECT radioligand may have affected outcome; the other study used 99m Tc-labeled hexamethyl propylene-amineoxime (HMPAO), and we used 99m Tc-ECD. 99m Tc-HMPAO must be constituted immediately before injection, and this delay results in more postictal injections than would occur with use of 99m Tc-ECD. 17 The conventional method of visually comparing ictal with interictal SPECT images has been reported to yield an abnormal focus in as many as 90% of patients with TLE, 18 whereas the rate of STATISCOM detection (84%) and SISCOM detection (66%) of an abnormal focus in our study are lower. However, many conventional visual comparison studies were not blinded to the results of all other diagnostic information, and the reference for localization was scalp EEG findings. In contrast, blinded reviews have demonstrated that the yield of the conventional visual comparison method is much lower than SISCOM (39% vs 88%). 4 The yield of SISCOM in our first validation study, conducted 12 years ago, was 88%, 4 which was higher than the yield of 66% in the current study. The previous study involved patients who were evaluated at Mayo Clinic from 1993 through 1996. Our current study involved patients evaluated from 1997 through 2005. As with other major epilepsy centers, we experienced a remarkable change in the complexity of the patient population undergoing epilepsy surgery, beginning about the mid 1990s. At this time, many major epilepsy centers reported an increase in the number of patients treated with intracranial electrode implantation. These changes have been attributed to the increased availability of epilepsy surgery nationwide in the 1990s, which has resulted in major medical centers evaluating epilepsies that were more complex than those previously encountered.
Our study showed that STATISCOM results have prognostic implications for epilepsy surgery outcome. Compared with incorrect or indeterminate STATISCOM localization, correct localization of the STATISCOM focus to the TLE subtype was associated with a higher probability of seizure-free outcome. Post hoc analysis also showed that of the 72 patients who had postsurgical follow-up of at least 1 year, 46 patients (64%) who had positive STATISCOM became seizure-free, whereas 33 patients (46%) with positive SISCOM became seizure-free (p Ͻ 0.05).
The absence of a relevant MRI lesion in patients with medically intractable epilepsy presents major challenges when localizing the seizure focus for epilepsy surgery. 19 Such a condition often requires functional imaging tests (ictal SPECT or fluorodeoxyglucose PET) to help guide intracranial electrode implantation and resective surgery. We showed that STATISCOM localized an abnormal focus in more patients with nonlesional MRI findings than SISCOM. Furthermore, the rate of correct localization to TLE subtype with STATISCOM was almost twice that of SISCOM (80% vs 47%).
The reviewers in our study were not specifically blinded to the fact that all study subjects had TLE. Therefore, our results may have resulted in a higher yield of STATISCOM and SISCOM findings than if the reviewers had been specifically blinded to the type of epilepsy being evaluated. The results of our study are applicable to patients with TLE, and the value of STATISCOM in extratemporal epilepsy needs further evaluation.
